Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
CAMBRIDGE, Mass., Feb. 10, 2016 -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the global collaboration agreement executed by the Company on January 8, 2016 with Mylan N.V.’s subsidiary, Mylan Ireland Limited, to develop and commercialize six biosimilar candidates.
With the early termination of the applicable waiting period under the HSR Act, the collaboration agreement with Mylan is effective as of February 9, 2016. Under the collaboration agreement, Mylan is obligated to pay Momenta a $45 million upfront cash payment within 30 days of the effective date.
Additional details regarding the collaboration can be found in Momenta’s Form 8-K filed with the Securities and Exchange Commission on January 8, 2016.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
MOMENTA INVESTOR CONTACT: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected] MOMENTA MEDIA CONTACT: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060 [email protected]
